Clinical trials: Cystitis, Interstitial, open to volunteers
- Condition Cystitis, Interstitial
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Interstitial Cystitis, Bladder Pain Syndrome
Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and…
- Trial name
- NCT05737121
- Testing
- VNX001, Lidocaine, Heparin
- Where
- 14 sites in United States
- Volunteers
- 120 people
- Sponsor
- Vaneltix Pharma, Inc.
Interstitial Cystitis, Chronic Pain
A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management
The purpose of this study is to evaluate if it is possible to use intravaginal high-density surface electromyography to guide Botulinum neurotoxin (BoNT) injection to treat pelvic floor muscle overactivity that complicates…
- Conditions
- Interstitial Cystitis, Chronic Pain, Pelvic Floor; Relaxation, Pelvic Floor Disorders
- Trial name
- NCT05062902
- Testing
- High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device, Botulinum Neurotoxin
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- HillMed Inc.
Interstitial Cystitis, Bladder Pain Syndrome
Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)
This is an open-label study that will enroll participants with Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS). The study will assess PRN (as needed) dosing of up to 6 intravesical (via catheter) doses of VNX001 (study…
- Trial name
- NCT06394830
- Testing
- VNX001
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vaneltix Pharma, Inc.